维力医疗
(603309)
| 流通市值：41.91亿 | | | 总市值：41.91亿 |
| 流通股本：2.92亿 | | | 总股本：2.92亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,191,172,720.75 | 745,161,624.74 | 348,152,134.38 | 1,509,335,256.03 |
| 营业收入 | 1,191,172,720.75 | 745,161,624.74 | 348,152,134.38 | 1,509,335,256.03 |
| 二、营业总成本 | 966,698,297.98 | 599,681,370.35 | 279,072,044.8 | 1,254,900,116.55 |
| 营业成本 | 664,906,561.63 | 409,560,013.62 | 192,256,355.32 | 837,189,388.83 |
| 税金及附加 | 15,471,485.99 | 10,123,699.17 | 4,320,619.64 | 16,313,055.07 |
| 销售费用 | 104,430,660.99 | 62,629,712.38 | 28,727,694.8 | 158,218,403.91 |
| 管理费用 | 98,956,730.23 | 62,914,737.54 | 30,232,203.45 | 129,920,814.45 |
| 研发费用 | 71,257,900.33 | 46,634,095.32 | 21,233,816.26 | 111,112,162.68 |
| 财务费用 | 11,674,958.81 | 7,819,112.32 | 2,301,355.33 | 2,146,291.61 |
| 其中:利息费用 | 10,913,575.51 | 8,786,344.13 | 2,346,564.4 | 12,315,532.14 |
| 其中:利息收入 | 5,102,843.49 | 3,264,530.51 | 1,142,746.16 | 5,631,835.85 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,100,977.01 | 326,183.14 | 628,851.62 | 619,061.73 |
| 加:投资收益 | 1,546,296.66 | 1,569,236.69 | 676,864.98 | 6,691,645.98 |
| 资产处置收益 | -101,235.34 | -2,304.82 | -2,304.82 | 428,433.91 |
| 资产减值损失(新) | -2,448,544.02 | -2,313,359.83 | -1,591,797.14 | -9,269,486.1 |
| 信用减值损失(新) | -320,039.75 | -263,362.4 | -57,850.18 | -18,466.35 |
| 其他收益 | 10,782,739.31 | 4,779,121.67 | 3,034,871.8 | 12,612,806.09 |
| 四、营业利润 | 235,034,616.64 | 149,575,768.84 | 71,768,725.84 | 265,499,134.74 |
| 加:营业外收入 | 350,095.2 | 292,090.78 | 58,221.63 | 347,683.57 |
| 减:营业外支出 | 459,317.5 | 320,410.22 | 124,480.18 | 2,803,286.49 |
| 五、利润总额 | 234,925,394.34 | 149,547,449.4 | 71,702,467.29 | 263,043,531.82 |
| 减:所得税费用 | 35,130,219.65 | 22,517,024.83 | 11,121,679.78 | 34,572,491.15 |
| 六、净利润 | 199,795,174.69 | 127,030,424.57 | 60,580,787.5 | 228,471,040.67 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 199,795,174.69 | 127,030,424.57 | 60,580,787.5 | 228,471,040.67 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 191,642,595.23 | 121,076,601.73 | 58,923,751.17 | 219,393,029.14 |
| 少数股东损益 | 8,152,579.46 | 5,953,822.84 | 1,657,036.33 | 9,078,011.53 |
| 扣除非经常损益后的净利润 | 184,371,840.43 | 117,620,532.54 | 56,645,532.5 | 210,024,675.08 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.65 | 0.41 | 0.2 | 0.75 |
| (二)稀释每股收益 | 0.65 | 0.41 | 0.2 | 0.75 |
| 八、其他综合收益 | 4,481,304.95 | 3,607,059.26 | 364,312.09 | -944,789.73 |
| 归属于母公司股东的其他综合收益 | 4,257,239.7 | 3,426,706.3 | 346,096.49 | -897,550.24 |
| 九、综合收益总额 | 204,276,479.64 | 130,637,483.83 | 60,945,099.59 | 227,526,250.94 |
| 归属于母公司股东的综合收益总额 | 195,899,834.93 | 124,503,308.03 | 59,269,847.66 | 218,495,478.9 |
| 归属于少数股东的综合收益总额 | 8,376,644.71 | 6,134,175.8 | 1,675,251.93 | 9,030,772.04 |
| 公告日期 | 2025-10-21 | 2025-07-31 | 2025-04-25 | 2025-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |